Sinaptica Therapeutics obtains FDA Breakthrough Device Designation for Alzheimer's treatment

The neurostimulation device, which is currently for investigational use only, aims to treat cognitive and functional decline in Alzheimer's patients.

from MobiHealthNews https://ift.tt/UbcnjZg
https://ift.tt/Pi4Jy5m